[Skip to Content]

Claim CME

Vaccination

Risk of Appendicitis After mRNA COVID-19 Vaccination in a Danish Population

Educational Objective
To identify the key insights or developments described in this article

1 Credit CME

JAMA Internal Medicine

Published Online: April 25, 2022

Research Letter

Article Information and Disclosures

Helene Kildegaard, MD¹;

Louise Ladebo, MScPharm, PhD¹;

Jacob Harbo Andersen, MSc¹;

Peter Bjødstrup Jensen, PhD¹;

Lotte Rasmussen, MScPharm, PhD¹;

Per Damkier, MD, PhD^1,2,3;

Anton Pottegård, MScPharm, DMSc^1,4

Author Affiliations

¹Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense
²Department of Clinical Pharmacology, Odense University Hospital, Odense, Denmark
³Department of Clinical Research, University of Southern Denmark, Odense
⁴Hospital Pharmacy Funen, Odense University Hospital, Odense, Denmark

Read article on JAMA Network

Read Article Claim CME

Claim CME

Sign in to take quiz and track your certificates

Buy This Activity

Article Information

Accepted for Publication: March 6, 2022.

Published Online: April 25, 2022. doi:10.1001/jamainternmed.2022.1222

Corresponding Author: Helene Kildegaard, MD, Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, J.B. Winsløws Vej 19/2, DK-5000 Odense C (hckildegaard@health.sdu.dk).

Author Contributions: Dr Kildegaard and Mr Pottegård had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Kildegaard, Rasmussen, Pottegård.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Kildegaard.

Critical revision of the manuscript for important intellectual content: Ladebo, Andersen, Jensen, Rasmussen, Damkier, Pottegård.

Statistical analysis: Kildegaard, Andersen, Jensen.

Obtained funding: Pottegård.

Administrative, technical, or material support: Ladebo.

Supervision: Pottegård.

Conflict of Interest Disclosures: Ms Rasmussen reported receiving support through the University of Southern Denmark from Novo Nordisk outside the submitted work. Mr Pottegård reported receiving grants from Alcon, Almirall, Astellas Pharma, AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Servier, and LEO Pharma outside the submitted work. No other disclosures were reported.

Additional Contributions: We thank Lars Christian Lund, MD, and Jesper Hallas, MD, from the University of Southern Denmark for valuable input into the methods used in this work. They were not compensated for their contributions.

References

US Food and Drug Administration. Vaccines and related biological products advisory committee December 10, 2020 meeting announcement. December 10, 2020. Accessed December 14, 2021. https://www.fda.gov/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-december-10-2020-meeting-announcement

Mitchell J , Yue QY . Appendicitis as a possible safety signal for the COVID-19 vaccines. Vaccine X. 2021;9:100122. doi:10.1016/j.jvacx.2021.100122 PubMed Google Scholar Crossref

Barda N , Dagan N , Ben-Shlomo Y , et al. Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N Engl J Med. 2021;385(12):1078-1090. doi:10.1056/NEJMoa2110475 PubMed Google Scholar Crossref

US Food and Drug Administration. COVID-19 vaccine safety surveillance. December 7, 2021, Accessed March 2, 2022. https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/covid-19-vaccine-safety-surveillance

Klein NP , Lewis N , Goddard K , et al. Surveillance for adverse events after COVID-19 mRNA vaccination. JAMA. 2021;326(14):1390-1399. doi:10.1001/jama.2021.15072 PubMed Google Scholar Crossref

Kleif J , Thygesen LC , Gögenur I . Validity of the diagnosis of appendicitis in the Danish National Patient Register. Scand J Public Health. 2020;48(1):38-42. doi:10.1177/1403494818761765 PubMed Google Scholar Crossref

AMA CME Accreditation Information

Credit Designation Statement: The American Medical Association designates this Journal-based CME activity activity for a maximum of 1.00  AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

1.00 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program;;
1.00 Self-Assessment points in the American Board of Otolaryngology – Head and Neck Surgery’s (ABOHNS) Continuing Certification program;
1.00 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program;
1.00 Lifelong Learning points in the American Board of Pathology’s (ABPath) Continuing Certification program; and
1.00 credit toward the CME [and Self-Assessment requirements] of the American Board of Surgery’s Continuous Certification program

It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting MOC credit.